title: The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.
abstract: For patients whose breast cancers are not responsive to endocrine therapy, there are a large number of cytotoxic drugs that will induce a response. In spite of the introduction of new, very active drugs such as the taxanes, vinorelbine, capecitabine, gemcitabine, and trastuzumab, the anthracyclines are still as active as any--and more active than most--drugs used to treat breast cancer. Their inclusion in combinations to treat early and advanced disease prolongs survival. However, they cause nausea, vomiting, alopecia, myelosuppression, mucositis, and cardiomyopathies. There is no evidence that increasing the dose of conventional anthracyclines or any other of the cytotoxics beyond standard doses will improve outcomes. Schedule may be more important than dose in determining the benefit of cytotoxics used to treat breast cancer. Weekly schedules and continuous infusions of 5-fluorouracil and doxorubicin may have some advantages over more intermittent schedules. Liposomal formations of doxorubicin reduce toxicity, including cardiotoxicity; theoretically they should also be more effective because of better targeting of tumor over normal tissues. Both pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]) and liposomal doxorubicin (Myocet [NPLD]) appeared to be as effective as conventional doxorubicin and much less toxic in multiple phase II and phase III studies. PLD has been evaluated in combinations with cyclophosphamide, the taxanes, vinorelbine, gemcitabine, and trastuzumab, and NPLD has been evaluated in combination with cyclophosphamide and trastuzumab. Both liposomal anthracyclines are less cardiotoxic than conventional doxorubicin. The optimal dose of PLD is lower than that of conventional doxorubicin or NPLD. Patients treated with PLD have almost no alopecia, nausea, or vomiting, but its use is associated with stomatitis and hand-foot syndrome, which can be avoided or minimized with the use of proper dose-schedules. In contrast, the optimal dose-schedule of NPLD is nearly identical to that of conventional doxorubicin. The toxicity profile of NPLD is similar to that of conventional doxorubicin, but toxicities are less severe and NPLD is better tolerated than conventional doxorubicin at higher doses.
authors.affiliation: The Cancer Center, Inova Fairfax Hospital, Falls Church, VA, USA.
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Robert
authors.forename: Charles L
authors.initials: CL
authors.lastname: Vogel
authors.forename: I Craig
authors.initials: IC
authors.lastname: Henderson
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Sparano
authors.forename: Melvin R
authors.initials: MR
authors.lastname: Moore
authors.forename: Paula
authors.initials: P
authors.lastname: Silverman
authors.forename: Beth A
authors.initials: BA
authors.lastname: Overmoyer
authors.forename: Charles L
authors.initials: CL
authors.lastname: Shapiro
authors.forename: John W
authors.initials: JW
authors.lastname: Park
authors.forename: Gail T
authors.initials: GT
authors.lastname: Colbern
authors.forename: Eric P
authors.initials: EP
authors.lastname: Winer
authors.forename: Alberto A
authors.initials: AA
authors.lastname: Gabizon
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000008:administration & dosage*; D006801:Humans; D008081:Liposomes
chemical_list: D000903:Antibiotics, Antineoplastic; D008081:Liposomes; D004317:Doxorubicin